GG
NTLA icon

Golden Green’s Intellia Therapeutics NTLA Stock Holding History

Golden Green’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,014
Closed -$356K – 116
2021
Q4 		$356K Buy
3,014
+1,160
+63% +$145K 0.29% 81
2021
Q3 		$249K Sell
1,854
-57
-3% -$8.63K 0.19% 123
2021
Q2 		$309K Buy
+1,911
New +$149K 0.24% 119
2021
Q1 		– Sell
-4,487
Closed -$244K – 184
2020
Q4 		$244K Buy
+4,487
New +$163K 0.23% 94

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Golden Green's NTLA Position: Q1 2022 in Review

Golden Green sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 3,014 shares — an estimated $356K sold.

Golden Green first reported a position in NTLA in Q4 2020 and held it in 4 quarters. The position peaked at $356K in Q4 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

  • Golden Green reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Golden Green sold 3,014 Intellia Therapeutics shares in Q1 2022, an estimated $356K.
  • Golden Green first reported a position in Intellia Therapeutics in Q4 2020 and held it in 4 quarters.
  • Golden Green's Intellia Therapeutics position peaked at $356K in Q4 2021.
  • 348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Golden Green's 13F filing for Q1 2022, filed 18 Apr 2022.